InterMune Inc $28.29

down -0.02


17/4/2014 08:10 PM  |  NASDAQ : ITMN  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get ITMN Trend Analysis - it has outperformed the S&P 500 by 196%

Partner Headlines

  1. Horizon Pharma To Buy Vidara, Join Exodus To Ireland

    IBD
  2. UPDATE: InterMune Announces Proposed Public Offering of 7.5M Shares

    Benzinga
  3. Benzinga's Top Upgrades

    Benzinga
  4. Benzinga's Weekend M&A Chatter

    Benzinga
  5. Precious Metals, Health Care Led Mutual Funds In Feb.

    IBD
  6. Weekly Insider Sells Highlight: BX, PCYC, MAS, ITMN

    GuruFocus
  7. Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE Moving ...

    Benzinga
  8. UPDATE: Credit Suisse Downgrades InterMune as Balanced Risk/Reward is Reflected ...

    Benzinga
  9. Benzinga's Top #PreMarket Losers

    Benzinga
  10. ETF Outlook For Wednesday, February 26, 2014 (BJK, TAN, EEM, FBT)

    Benzinga
  11. InterMune soars on drug trial

    IBD
  12. Mid-Afternoon Market Update: Markets Turn Red as Tesla Continues to Rip ...

    Benzinga
  13. Mid-Day Market Update: US Stocks Mostly Flat; Office Depot Shares Decline ...

    Benzinga
  14. Mid-Morning Market Update: Markets Fall; Home Depot Profit Beats Estimates

    Benzinga
  15. InterMune Stock Doubles As Drug Fights Lung Disease

    IBD
  16. Benzinga's Volume Movers

    Benzinga
  17. UPDATE: InterMune Reports Phase 3 ASCEND Trial Results of Pirfenidone in ...

    Benzinga
  18. Mid-Afternoon Market Update: Boyd Gaming Rallies as Amazon Falls After ...

    Benzinga
  19. Market Wrap For January 10: Job Growth Weak, But Unemployment Falls

    Benzinga
  20. Stifel Maintains on InterMune

    Benzinga
  21. InterMune Prices 6.5M Share Offering at $13.00/Share

    Benzinga
  22. InterMune Announces 6.5M Share Offering

    Benzinga
  23. UPDATE: Stifel Nicolaus Cuts PT to $19 on InterMune on Esbriet Pre-Announcement

    Benzinga
  24. InterMune Reports Preliminary Fourth Quarter 2012 Esbriet Revenue And Other ...

    Benzinga
  25. InterMune Inc. Reports Operating Results (10-Q)

    GuruFocus
  26. InterMune Soars 19 Percent After Q3 Earnings Results

    Benzinga
  27. Mid-Afternoon Market Update: Stocks Remain Lower

    Benzinga
  28. UPDATE: Canaccord Genuity Upgrades InterMune to Buy on Esbriet EU Momentum

    Benzinga
  29. Health Canada Approves Esbriet as First Treatment for Fatal Lung Disease

    Benzinga
  30. InterMune Reports New Analyses from the RECAP Study of Esbriet at ERS

    Benzinga
  31. Manchester United, InterMune Among Stocks hitting 52-Week Lows Monday

    FoxBusiness
  32. Facebook Inc. - Class A, Molycorp Among Stocks falling to Annual Lows Friday

    FoxBusiness
  33. ProShares Trust Ultra VIX Short Term Futures ETF, Thompson Creek Metals ...

    FoxBusiness
  34. InterMune Inc. Reports Operating Results (10-Q)

    GuruFocus
  35. UPDATE: Stifel Nicolaus Reduces PT to $23 on InterMune

    Benzinga
  36. UPDATE: Canaccord Genuity Downgrades InterMune to Hold

    Benzinga
  37. InterMune (ITMN) Loses 12.4% After POsting Larger-Than-Expected Loss

    MarketIntelligenceCenter
  38. Health Care Sector Wrap

    FoxBusiness
  39. Banco Bradesco, Barclays Among Stocks Down on Above-average Volume Monday

    FoxBusiness
  40. Social Media Outlook for Monday July 23 (ITMN, NRG, H, HAS)

    Benzinga
  41. InterMune's 2Q Results: Postgame Scorecard

    FoxBusiness
  42. InterMune 2Q Earnings Pregame Scorecard

    FoxBusiness
  43. Shionogi Files Complaint Against InterMune -8K

    Benzinga
  44. Sweden's Dental and Pharmaceutical Benefits Agency Authorizes Reimbursement ...

    Benzinga
  45. A Peek Into The Market Before The Trading Starts

    Benzinga
  46. InterMune Completes Divestiture of Actimmune; Provides 2012 Expense Guidance

    Benzinga
  47. Intermune Will Divest Rights to Vidara for $55M in Cash, Plus 2 Year Royalty ...

    Benzinga
  48. InterMune (ITMN) Loses 8.1% on Further Delay to Esbriet Trial

    MarketIntelligenceCenter
  49. InterMune

    IBD
  50. InterMune (ITMN) Gains 13.3% on German Ruling on Drug's Effectiveness

    MarketIntelligenceCenter
Trading Center